Skip to Contents

Meet Us at the Joint Congress of ESPE(European Society for Paediatric Endocrinology) and ESE(European Society of Endocrinology) 2025

Meet Us at the Joint Congress of ESPE(European Society for Paediatric Endocrinology) and ESE(European Society of Endocrinology) 2025.

An Ongoing Phase 2 Study of Efpegerglucagon: Promising Results on Safety and Efficacy in Subjects with Congenital Hyperinsulinism
Poster Number
RC3.2a
Session
Poster section Fetal and Neonatal Endocrinology, Saturday, May 10 15:00 - 20:00 CEST/ Sunday, May 11 from 08:00 CEST, Poster Hall C
Presenter
Antonia Dastamani / Great Ormond Street Hospital

Antonia.Dastamani@gosh.nhs.uk

An Ongoing Phase 2 Study of Efpegerglucagon: Promising Results on Safety and Efficacy in Subjects with Congenital Hyperinsulinism
Presentation
RC3.2
Session
Rapid Communications, Sunday, 11 May, 14:20 - 14:25 CEST, D5
Presenter
Antonia Dastamani / Great Ormond Street Hospital

Antonia.Dastamani@gosh.nhs.uk

Hanmi's New Story

Creativity, Innovation, and Challenge
A New Era Takes Off at Hanmi

Focus on Making
Innovative Medicines

Hanmi Pharmaceutical is leading innovation in the
pharmaceutical industry with a sustainable R&D
infrastructure covering various therapeutic areas.

Obesity/Metabolism

Developing best-in-class drugs for obesity,
non-alcoholic steatohepatitis,
and more with multiple mechanisms of action

View More

ESG Report

Hanmi ESG is Everyday-life Innovation

View More

Your dream is our future.
Hanmi awaits you.

Join Us